Biopharma M&A is back and IPOs are possible, but most biotechs aren’t out of the woods.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser . In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Most deals focus on late-stage or marketed assets, as pharma buyers attempt to fill gaps left by blockbusters set to lose patent exclusivity. There’s resurgent interest in treatments for chronic, widespread conditions across immunology and cardio-metabolic diseases, although rare diseases remain popular among some buyers. Initial public offerings and follow-on public financings are also reappearing, as investors take confidence from pharma’s renewed M&A activity.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Hair loss treatments take aim at the immune system - Nature BiotechnologyDrugs commonly used in rheumatology, the JAK inhibitors, are opening up treatment options for people with autoimmune-driven hair loss, and new mechanistic knowledge is also helping scientists tackle androgenic alopecia, the commonest cause of baldness.
Les mer »
Drugs catch a ride through the blood–brain barrier - Nature BiotechnologyA new era of brain-penetrant therapies is opening up, as companies hook up drugs to transferrin receptors or use viral capsids to hitch a ride into previously inaccessible regions.
Les mer »
A genome-wide view of disordered proteins - Nature BiotechnologyTranscription factors containing disordered regions can now be mapped across the genome, aiding functional studies.
Les mer »
Survival of the fittest glia - Nature BiotechnologyHuman glial progenitors transplanted into a chimeric mouse brain replace sick or older human glia, a finding that could one day lead to new treatments for neurological disease.
Les mer »
Methodological concerns and lack of evidence for single-synapse RNA-seqNature Biotechnology - Methodological concerns and lack of evidence for single-synapse RNA-seq
Les mer »
Reply to: Methodological concerns and lack of evidence for single-synapse RNA-seqNature Biotechnology - Reply to: Methodological concerns and lack of evidence for single-synapse RNA-seq
Les mer »